In this study, we further characterized the anti-PD-L1 x EGFR bispecific Nanofitin, previously described to exhibit higher in vitro tumor cell selectivity and superior anti-tumor cell activity as compared to the monomeric anti-PD-L1 Nanofitin alone [10]. Here, EGFR is linked to neoplasm.